If you are taking Zantac, you should be aware that the FDA and the European Union are investigating whether the heartburn medication, as well as generic versions of the drug, contain high enough levels of the cancer-causing agent NDMA, (N-Nitrosodimeethylamine), to pose a danger to patients.
Zantac, or Ranitidine, as it is called in generic form, is an antacid and antihistamine used by thousands of people to prevent heartburn and gastrointestinal issues. More troubling is the fact that it is sometimes given to infants suffering from reflux. Now, the medication, which is sold at major pharmacies such as Walgreens, CVS, and Walmart, is under investigation by European and U.S. health regulators.
U.S. drug safety officials became aware of the potential problem when Valisure, a Connecticut based online pharmacy that independently tests every medication it dispenses, alerted the FDA that its testing had found high levels of NDMA, a carcinogen, in Zantac and generic versions of the drug.